WendellandCarolyn/iStock Editorial via Getty Images Kroger ( NYSE: KR ) has followed Costco Wholesale ( NASDAQ: COST ) in offering popular GLP-1 drugs such as Wegovy and Zepbound, developed by Novo Nordisk ( NVO ) and Eli Lilly ( LLY ), as part of a revamped weight management program. In a statement on Friday, the company said eligible patients will be able to access weight loss drugs, including Wegovy and Zepbound, as part of the program, available at a starting price of $99 per visit. Kroger Health's The Little Clinic unit, which operates about 226 clinics across nine states, is tasked with running the new program via in-person and telehealth consultations.
In April, Costco ( COST ) also announced a new weight loss program to offer its members access to GLP-1 drugs in partnership with healthcare marketplace Sesame. The renewable program was launched at a three-month subscription fee of $179. More on Kroger Kroger: Downside Risk Mounts As Merger Poses Lose-Lose Scenario Kroger Deserves More Love Kroger: Albertsons Merger Creates Highly Skewed Return Potential (Technical Analysis) Kroger drivers at Michigan fulfillment center vote to unionize GoodRx enters agreement with Kroger for improved prescription pricing.
